# LIMINATUS PHARMA, INC. (LIMN) · Edgar & Edgarette company card

> Figures from the company's own SEC filings.

SEC CIK 1971387 · fiscal year ended — · 0 audited years read · [page](https://www.pops4.com/boards/company/LIMN) · [JSON](https://www.pops4.com/boards/company/LIMN.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | — |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | — |
| Net margin | — |
| Operating cash flow | — |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | — |
| Total assets | — |
| Total equity | — |
| Equity ÷ assets | — |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures


## Edgarette's reading

The filings carry no annual revenue line Edgarette can read (common for banks and insurers, which report income differently). Nothing weighed, nothing guessed.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 6, latest 2026-09-29 ([filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/0001104659-26-111665-index.htm))

## Recent filings

- 8-K · filed 2026-11-03 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926122012/0001104659-26-122012-index.htm)
- 8-K · filed 2026-09-29 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926111665/0001104659-26-111665-index.htm)
- 8-K · filed 2026-08-18 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926098335/0001104659-26-098335-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926097304/0001104659-26-097304-index.htm)
- 8-K · filed 2026-08-04 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/0001104659-26-090423-index.htm)
- 8-K · filed 2026-07-30 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1971387/000110465926088380/0001104659-26-088380-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001971387.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1971387

## Cite

POPS4, Edgar & Edgarette: LIMINATUS PHARMA, INC. (LIMN) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/LIMN. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.